Surufatinib plus chemo-immunotherapy before chemoradiation for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of treatments for people with advanced esophageal cancer that can't be removed by surgery. It uses a targeted therapy called surufatinib along with chemo-immunotherapy and radiation to see if it can shrink the tumor before further treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell esophageal cancer that has spread locally but not to distant organs.
- You are between 18 and 80 years old.
- You have not had any previous chemotherapy, radiation, surgery, targeted therapy, or immunotherapy for this cancer.
- Your lungs, kidneys, and bone marrow are working well enough based on standard blood and lung function tests.
- You are in good general health (able to do everyday activities) with an ECOG score of 0 or 1.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug toripalimab and the chemotherapy pill capecitabine after standard chemoradiotherapy can help prevent esophageal cancer from coming back. It's for people with squamous cell esophageal cancer that hasn't spread far and who have just finished chemoradiotherapy.
This trial tests a new immunotherapy drug called toripalimab, given before, during, and after standard radiation and chemotherapy for esophageal cancer that hasn't spread. The goal is to see if adding this drug can improve outcomes for patients.
This trial tests a personalized treatment approach for advanced esophageal cancer that has stopped responding to immunotherapy. It aims to find better options for people whose cancer has progressed after standard treatments.
This trial tests two drugs, sacituzumab tirumotecan and toripalimab, given before surgery for esophageal cancer that has spread nearby but is still removable. The goal is to see if this combination shrinks the tumor and improves outcomes.
This trial compares the usual treatment (chemotherapy plus radiation before surgery) with a combination that also includes an immunotherapy drug called sintilimab. The goal is to see if adding immunotherapy helps shrink the tumor and improve outcomes for patients with esophageal cancer that can be removed by surgery.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
Hear when a new Toripalimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.